GBA1 and Parkinson disease: Non-inhibitory SMC LTI-291, which modulates GCase post-translational folding by binding to sites other than the active site, is being evaluated in GBA1-PD patients by Lysosomal Therapeutic Inc. (Netherlands Trial Register: NTR6960 and NTR7299).